Financial Incentives for Smoking Treatment
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Smoking Cessation
- Sponsor
- University of California, Los Angeles
- Enrollment
- 1058
- Locations
- 2
- Primary Endpoint
- Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
- Status
- Enrolling By Invitation
- Last Updated
- 2 years ago
Overview
Brief Summary
Financial incentives for motivating changes in health behavior, particularly for smoking and other morbid habits, are increasingly being tested by health insurers, employers, and government agencies. However, in using incentive programs for smoking cessation, key unanswered structural and theoretical questions remain regarding their effectiveness, acceptability to patients, and economic sustainability. This trial aims to advance the science and implementation of financial incentives for smoking cessation interventions among high-risk, hospitalized smokers. The investigators will pursue two specific aims: 1) comparing the impact of three approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life and 2) comparing the short-term and long term return on investment of using goal directed and outcome-based financial incentives to promote smoking cessation.
Investigators
Soma Wali
Principal Investigator
University of California, Los Angeles
Eligibility Criteria
Inclusion Criteria
- •age ≥ 18 years
- •smoked tobacco during the prior 30 days,
- •have an active U.S. phone number and address,
- •can provide consent in English or Spanish and
- •are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit
Exclusion Criteria
- •use only smokeless tobacco,
- •are pregnant or breastfeeding,
- •are discharged to an institution (e.g., nursing home, long-term care facility),
- •are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study
Outcomes
Primary Outcomes
Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
Time Frame: 6 months
Assessed by self-report questionnaire, and biochemically verified by salivary cotinine
Secondary Outcomes
- Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis)(12 months)
- Use of evidence based treatment (e.g. counseling and smoking cessation medications) assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report(2 months)
- Quality of life as measured by PROMIS-29 Profile v2.0(12 months)
- Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis)(3 years)